The lancet. Diabetes & endocrinology最新文献

{"title":"Dapagliflozin in patients with COVID-19: mind the kidneys.","authors":"Thiago Reis, Marlies Ostermann, Alexander Zarbock, John A Kellum, Claudio Ronco","doi":"10.1016/S2213-8587(21)00329-6","DOIUrl":"https://doi.org/10.1016/S2213-8587(21)00329-6","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"97-98"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39735988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding decreasing mortality in people with diabetes.","authors":"Jennifer Manne-Goehler, David Flood","doi":"10.1016/S2213-8587(22)00001-8","DOIUrl":"https://doi.org/10.1016/S2213-8587(22)00001-8","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"87-88"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39818367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sufyan Hussain: co-creating possibilities.","authors":"Ray Cavanaugh","doi":"10.1016/S2213-8587(21)00348-X","DOIUrl":"https://doi.org/10.1016/S2213-8587(21)00348-X","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"100"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39847648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How do clinicians integrate oral octreotide into their treatment plan for acromegaly?","authors":"Maya B Lodish","doi":"10.1016/S2213-8587(21)00319-3","DOIUrl":"https://doi.org/10.1016/S2213-8587(21)00319-3","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"86-87"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39850262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The power of resilience.","authors":"The Lancet Diabetes Endocrinology","doi":"10.1016/S2213-8587(22)00010-9","DOIUrl":"https://doi.org/10.1016/S2213-8587(22)00010-9","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"85"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39912992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.","authors":"Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, Samvel B Gasparyan, Remo H M Furtado, Subodh Verma, Otavio Berwanger","doi":"10.1016/S2213-8587(21)00326-0","DOIUrl":"https://doi.org/10.1016/S2213-8587(21)00326-0","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"98-99"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39735989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.","authors":"Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut, Yulia G Pokramovich, Mark E Molitch, Nina Leonova, Gerald Raverot, Elena Grineva, Yury E Poteshkin, Yossi Gilgun-Sherki, William H Ludlam, Gary Patou, Asi Haviv, Murray B Gordon, Nienke R Biermasz, Shlomo Melmed, Christian J Strasburger","doi":"10.1016/S2213-8587(21)00296-5","DOIUrl":"https://doi.org/10.1016/S2213-8587(21)00296-5","url":null,"abstract":"<p><strong>Background: </strong>Despite biochemically responding to injectable somatostatin receptor ligands (iSRLs), many patients with acromegaly experience treatment burdens. We aimed to assess maintenance of biochemical response and symptomatic control with oral octreotide capsules versus iSRLs in patients with acromegaly who previously tolerated and responded to both.</p><p><strong>Methods: </strong>This global, open-label, randomised controlled phase 3 trial was done in 29 clinical sites in Austria, France, Germany, Hungary, Italy, Lithuania, Russia, Serbia, Spain, and the USA. Eligible patients were adults aged 18-75 years with acromegaly who were receiving iSRLs (long-acting octreotide or lanreotide autogel) for at least 6 months before baseline with a stable dose for at least 4 months, and were deemed to be biochemically responding (insulin-like growth factor I [IGF-I] <1·3 × upper limit of normal [ULN] and mean integrated growth hormone <2·5 ng/mL). In the 26-week run-in phase, all patients received oral octreotide (40 mg a day, optional titration to 60 or 80 mg a day). Eligibility for the randomised treatment phase was completion of the run-in phase as a biochemical responder (IGF-I <1·3 × ULN and mean integrated growth hormone <2·5 ng/mL at week 24) and investigator assessment of acromegaly being adequately controlled. Patients were randomly assigned (3:2) to oral octreotide capsules or iSRL at the same dose and interval as before enrolment. Randomisation and drug dispensing were conducted through a qualified randomisation service provider (eg, interactive web or voice response system). The primary endpoint was a non-inferiority assessment (margin -20 percentage points) of proportion of participants maintaining biochemical response throughout the randomised treatment phase (IGF-I <1·3 × ULN using time-weighted average; assessed by comparing the lower bound of the 2-sided 95% CI for the difference in biochemical response between groups). IGF-I was assessed once a month during the run-in and randomised treatment phases (single sample). Efficacy and safety assessments were performed on the randomised population. This trial is registered with ClinicalTrials.gov, NCT02685709.</p><p><strong>Findings: </strong>Between Feb 11, 2016, and Aug 20, 2020, 218 patients were assessed for eligibility. 72 patients were excluded, and 146 participants were enrolled into the run-in phase. 116 patients completed the run-in phase and 30 participants discontinued treatment. 92 participants were randomly assigned to oral octreotide (n=55) or iSRL (n=37). 50 (91%) of 55 participants who received oral octreotide (95% CI 44-53) and 37 (100%) of 37 participants who received iSRLs (34-37) maintained biochemical response. The lower bound of the 2-sided 95% CI for the adjusted difference in proportions between the two treatment groups achieved the prespecified non-inferiority criterion of -20% (95% CI -19·9 to 0·5). 19 (35%) of 55 participants in the oral octreotid","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"102-111"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39850263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D supplementation and mortality.","authors":"Inez Schoenmakers","doi":"10.1016/S2213-8587(22)00002-X","DOIUrl":"https://doi.org/10.1016/S2213-8587(22)00002-X","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"88-90"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39818372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2022; 10: 142-48.","authors":"","doi":"10.1016/S2213-8587(22)00011-0","DOIUrl":"https://doi.org/10.1016/S2213-8587(22)00011-0","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"e2"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39741014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of mortality in people with type 1 and type 2 diabetes by age of diagnosis: an incident population-based study in England and Wales.","authors":"Naomi Holman, Sarah H Wild, Edward W Gregg, Jonathan Valabhji, Naveed Sattar, Kamlesh Khunti","doi":"10.1016/S2213-8587(21)00293-X","DOIUrl":"https://doi.org/10.1016/S2213-8587(21)00293-X","url":null,"abstract":"","PeriodicalId":519532,"journal":{"name":"The lancet. Diabetes & endocrinology","volume":" ","pages":"95-97"},"PeriodicalIF":44.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39926072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}